Ending TB Means Investing in R&D
Joint statement from Aeras, FIND and TB Alliance
Advancing New TB Vaccines for the World
New on the Blog
The World Health Organization 2017 Global TB Report Highlights Funding Gaps and the Need to Accelerate Progress.
Take 1.5 minutes to watch our new animated video about how TB vaccines could help save 1.5 million lives. Add your voice to the fight!
Progress in the Pipeline
Together with our partners, we've made significant advances over the past decade using diverse and innovative strategies.
Collaboration for Innovation.
View this slideshow and see how we can change the lives of more than 8.6 million people.
TB is more complex than ever.
TB is becoming more complex and difficult to treat. The rise in multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains is making the disease harder and exponentially more expensive to fight and presents a threat to health in every country.
We are a nonprofit biotech advancing TB vaccines.
With a focus on innovation and impact, Aeras works with leading partners around the world to develop new TB vaccines that will be affordable and accessible to all who need them.
Vaccines are the most cost-effective approach.
TB will not be eliminated without successful new vaccines for both adults and children.
We collaborate within a vast network.
Aeras serves as a catalyst by investing in the world’s most promising TB vaccine candidates and collaborating to strengthen and advance the global pipeline.